Among them, CD3 is considered to be the primary target. Image Credit: ACROBiosystems CD3 molecules tend to bind to TCR non-covalently to develop a TCR/CD3 receptor complex on the T-cell’s surface.

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...

Rep. Jeff Hurd, the Republican representing Colorado’s 3rd Congressional District in the U.S. House of Representatives, ...

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers ...

In addition, the association of CD3 with the TCR–peptide–MHC complex transmits the activation signal to intracellular signalling molecules to initiate a signalling cascade in the T cell.

Shares of Tiziana Life Sciences (NASDAQ:TLSA) jumped 12% Thursday after the company said that a study of its drug candidate intranasal foralumab in the treatment of traumatic brain injury has been ...

A new study suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI). By studying the effects of the nasal anti-CD3 in a ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.